Thermo Fisher Scientific Inc · NYSE:TMO
Thermo Fisher Scientific — Merger or Acquisition (March 2020)
10 slides from Thermo Fisher Scientific's merger presentation, Mar 3, 2020
Slide 1: Thermo Fisher Scientific to Acquire QIAGEN N.V.
The world leader in serving science Thermo Fisher Scientific to Acquire QIAGEN N.V. March 3, 2020
Slide 2: Use of non-GAAP financial measures / forward looking statements
2 Use of non - GAAP financial measures / forward looking statements Use of Non - GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), Thermo Fis her uses certain non - GAAP financial measures, including adjusted EP
Slide 3: Tender offer notice
3 The tender offer referenced herein has not yet commenced. This communication is for informational purposes only and is neith er an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials t
Slide 4: Acquisition of QIAGEN – Creating Customer & Shareholder Value
4 • QIAGEN – a leading global provider of molecular diagnostics and sample preparation technologies • Complementary offering strengthens our unique value proposition for clinical and life sciences customers • Net purchase price of approximately $11.5B in cash • Creates significant shareholder value:
Slide 5: QIAGEN Overview
5 89% Revenue by Product 11% Consumables Instruments / Services QIAGEN Overview 21% 32% 47% EMEA Americas Asia Pacific / Rest of World Revenue by Geography • A leading global provider of molecular diagnostics and sample preparation technologies • Product portfolio serves high - growth markets • 2019
Slide 6: Strategic Rationale for Acquisition of QIAGEN
6 Strategic Rationale for Acquisition of QIAGEN • Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing • Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies •
Slide 7: Complementary Offerings Create Significant Customer Benefits
7 Complementary Offerings Create Significant Customer Benefits Clinical Life Sciences Customer and Patient Benefits • Biosciences – leading life science reagents and consumables offering • Genetic analysis technologies (including qPCR, NGS, Sanger and microarrays) • Leading sample preparation techno
Slide 8: Compelling Financial Profile
8 Compelling Financial Profile Price • Total cash consideration of approximately US $11.5B • €39 per fully diluted share • Assumption of $1.4B of net debt Returns • Attractive return profile and accretive to adjusted EPS • Expected to add $0.60 to adjusted EPS in first 12 months after close Synergie
Slide 9: Transaction Overview
9 Transaction Overview Financing • Fully committed bridge facility in place • Permanent financing from available cash and issuance of new debt Leverage • Pro forma leverage ratio expected to be approximately 3x at close • Expect to maintain investment - grade debt ratings post close Path to Completi
Slide 10: Acquisition of QIAGEN – Creating Customer & Shareholder Value
10 • QIAGEN – a leading global provider of molecular diagnostics and sample preparation technologies • Complementary offering strengthens our unique value proposition for clinical and life sciences customers • Net purchase price of approximately $11.5B in cash • Creates significant shareholder value
Thermo Fisher Scientific — Merger or Acquisition (March 2020) on 6ix